The genomic examination of FH patients at risk for PCSK9/LDLR and APOB polymorphisms has become necessary to ameliorate clinical diagnosis and management by considering the use of PCSK9 inhibitors in their therapeutic care plan. This evidence concerns the gene LDLR and familial hyperaldosteronism.